Interferon alfa-2b biosimilar (Fiocruz/Bio-Manguinhos)

干扰素α-2b生物类似药 (Fiocruz/Bio-Manguinhos)

Report date: 2022/01/24 09:34:29

Base Information

Drug NameInterferon alfa-2b biosimilar (Fiocruz/Bio-Manguinhos)
Drug Alias Name干扰素α-2b生物仿制药 (Fiocruz/Bio-Manguinhos)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCarcinoma, Renal CellMelanomaLeukemia, Myelogenous, Chronic +[7] 
Global Approved IndicationsCarcinoma, Renal CellMelanomaLeukemia, Myelogenous, Chronic +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryBrazil
Original Approved Date2006/01/01
Country/TerritoryBrazil
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFundacao Oswaldo Cruz (Fiocruz)
China Registration ClassN/A

Develop Information

Active CompaniesFundacao Oswaldo Cruz (Fiocruz)
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellMelanomaLeukemia, Myelogenous, Chronic +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A